Sign In
Buy TCRX
$0.743
-0.0127 (-1.68%)
At Close: Jul 31, 2026
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
07:00am, Monday, 31'st Mar 2025
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
07:00am, Thursday, 27'th Mar 2025
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience
TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025
11:31am, Friday, 07'th Mar 2025
Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barr
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
09:25am, Wednesday, 05'th Mar 2025
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.21 per share a year ago.
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
07:00am, Wednesday, 05'th Mar 2025
Presented updated data from ongoing ALLOHA™ Phase 1 heme trial at the 66 th ASH Annual Meeting and Exposition IND application cleared for seventh TCR in PLEXI-T™ Phase 1 solid tumor program; TSC-2
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
07:00am, Thursday, 27'th Feb 2025
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
07:00am, Tuesday, 18'th Feb 2025
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting
03:14am, Monday, 10'th Feb 2025
TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia, showing promising phase 1 results but potential GvHD risks. TCRX's financials are
Here's Why TScan Therapeutics (TCRX) is Poised for a Turnaround After Losing -5.63% in 4 Weeks
10:35am, Friday, 10'th Jan 2025
The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
07:00am, Thursday, 26'th Dec 2024
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
07:00am, Monday, 23'rd Dec 2024
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 New non-dilutive structure replaces existing convertible facility maturing in 2026
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14)
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
08:00am, Thursday, 05'th Dec 2024
WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cel
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates
09:26am, Tuesday, 12'th Nov 2024
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.24 per share a year ago.
